Resources from the same session
1529MO - The genomic landscape of small cell lung cancer in never smoking patients
Presenter: Michael Oh
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
930MO - PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091
Presenter: Solange Peters
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
933MO - Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer
Presenter: Myung-Ju Ahn
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 1529MO, 930MO and 933MO
Presenter: Antonio Passaro
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
LBA71 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
Presenter: Gerard Zalcman
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
931MO - Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study
Presenter: Kiyotaka Yoh
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
929MO - Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study
Presenter: Jonathan Spicer
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
932MO - Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
Presenter: Enriqueta Felip
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA50 - Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816
Presenter: Janis Taube
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 929MO, 932MO and LBA50
Presenter: Kersti Oselin
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast